Subscribe
shutterstock_1826152031_lev_radin
Lev Radin / Shutterstock.com
2 January 2024Big PharmaMarisa Woutersen

Regeneron prevails in eye treatment dispute and immediately launches new suit

District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UPC judge and Regeneron counsel urge lobbying to improve court's transparency
23 November 2023   Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.
Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.
Big Pharma
UPC judge and Regeneron counsel urge lobbying to improve court's transparency
23 November 2023   Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.

More on this story

Americas
Court dismisses Regeneron’s antitrust countersuit against Novartis
3 February 2022   Novartis escaped an antitrust countersuit brought by Regeneron earlier this week, with a New York court dismissing the suit which had been filed in response to Novartis’ patent complaint.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.
Big Pharma
UPC judge and Regeneron counsel urge lobbying to improve court's transparency
23 November 2023   Judge encourages lawyers and public to make their voices heard over transparency concerns | Awkward access to public hearings ‘causing problems’ says Regeneron counsel | Plea for public virtual hearings as judge notes that requests have been ‘coming in by the dozen’ | Panellists discuss at LSPN Europe.

More features

Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
HLK adds CRISPR specialist as partner
UPC delivers first 'imminent infringement' decision in biosimilar dispute